Company Overview of Tocagen Inc.
Tocagen Inc. is a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of gene therapy products for the selective treatment of cancer. The company focuses on developing a treatment for high grade glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more dist...
3030 Bunker Hill Street
San Diego, CA 92109
Founded in 2007
Key Executives for Tocagen Inc.
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2014.
Tocagen Inc. Key Developments
Tocagen Inc. Appoints Franklin M. Berger to the Board of Directors
Dec 2 14
Tocagen Inc. announced that Franklin M. Berger has been appointed to the board of directors. Mr. Berger will also serve as the chairman of a newly formed audit committee responsible for overseeing Tocagen's accounting, financial reporting, disclosure and financial risk management activities. He previously served as managing director, equity research, and senior biotechnology analyst at J.P. Morgan Securities from 1998 to 2003. Presently, Mr. Berger serves on the board of directors of Immune Design and Five Prime Therapeutics. He has served on the board of directors for numerous companies, including Seattle Genetics Inc. Mr. Berger is a founder and managing director of FMB Research and previously co-founded the small-cap focused NEMO fund at Sectoral Asset Management.
Tocagen Inc. Appoints Faheem Hasnain as Chairman of the Board of Directors
Nov 14 14
Tocagen Inc. announced that Faheem Hasnain, president and chief executive officer of Receptos Inc. has been appointed as chairman of the board of directors. Mr. Hasnain is a distinguished industry leader with over 30 years of experience in the biopharmaceutical industry. Presently, he serves as chairman of the board of Sente Inc. Previously, he was chairman of the board of Ambit Biosciences Corporation, acquired by Daiichi Sankyo Company, and he served on the board of directors of Seragon Pharmaceuticals, acquired by Roche; Aragon Pharmaceuticals, acquired by Johnson & Johnson; and Tercica Inc., acquired by Ipsen. Prior to joining Receptos, Mr. Hasnain was the president and chief executive officer and a director of Facet Biotech.
Tocagen Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 10:30 AM
Sep 12 14
Tocagen Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 10:30 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Speakers: Harry E. Gruber, Co-Founder, Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|